What we do Remedium Lifecare Ltd is a pharmaceutical company trading in Active Pharmaceutical Ingredients (APIs), intermediates and raw materials for pharma manufacturing serving domestic and international markets. |
Founded in 1,988 |
Market share Key player in API and intermediates trading with a growing footprint in domestic and regulated international markets. |
Problem solved Provides essential pharmaceutical raw materials and intermediates ensuring supply chain reliability for innovators and generic drug manufacturers. |
Top clients or who we serve Serves pharmaceutical manufacturers including generic and innovator companies in domestic and global regulated markets (B2B). |
Key management Mr. Adarsh Munjal (Whole Time Director) and Mr. Mansoor Abdul Vahab (Director) lead the company. |
Our journey and innovations Started in 1988, rebranded in 2020, shifted focus from Air-O-Water machines to pharma intermediates, and expanded internationally with a Singapore subsidiary in 2024. |
Where we operate Operations in India with export reach to international regulated markets and subsidiary in Singapore for expansion. |
Top products or what we offer Trading in APIs, advanced pharmaceutical intermediates, and essential chemicals like Iso propyl Alcohol, Cyclohexane, and others for pharma production. |
Top brands - |
Raw materials needed APIs and pharmaceutical chemical intermediates such as Iso propyl Alcohol, Cyclohexane, Ethyl Acetate among others. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue largely recurring through consistent supply contracts in the pharmaceutical industry. |
Our industry position Growing trading company with expanding market presence in pharma raw materials and intermediates segment. |
Financial highlights FY 2024-25 revenue approximately Rs. 405 crore with net profit around Rs. 2.13 crore; focus on scaling operations and profitability. |
Geographical revenue split - |
Order book - |
Whats driving growth Growing pharmaceutical demand, shift to regulated markets, business model pivot to APIs and contract manufacturing. |
Our future plans Expanding product portfolio, increasing international footprint via Singapore subsidiary, and growing pharma raw material trading. |
Our green promise - |
Our people and values Focus on corporate governance and compliance with a professional leadership team driving growth. |
Key challenges ahead Intense competition, regulatory compliance in international markets, and maintaining profitability amid raw material price volatility. |
Interesting facts Converted from Roxy Exports Limited in 2020 coinciding with business transition to pharma sector; recently issued large bonus shares to equity shareholders. |
Risks and strategy Mitigate supply chain risks and market fluctuations by diversifying products and expanding regulated market reach. |
